Hamilton Lane Inc (NASDAQ:HLNE) reported mixed results for the fourth quarter on Thursday.

On May 21, 2026, Hamilton Lane Inc (HLNE) shares rose 4.1% to a current price of $88.49. The stock has experienced significant volatility over the past year, tr

Hamilton Lane Incorporated (HLNE) Q4 2026 Earnings Call Transcript

Hamilton Lane NASDAQ: HLNE reported higher fiscal 2026 revenue and earnings growth, while management used the company's fiscal fourth-quarter earnings call to push back against concerns about private markets and highlight momentum in its evergreen fund platform.

While the top- and bottom-line numbers for Hamilton Lane (HLNE) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Hamilton Lane (HLNE) came out with quarterly earnings of $1.49 per share, beating the Zacks Consensus Estimate of $1.43 per share. This compares to earnings of $1.21 per share a year ago.

CONSHOHOCKEN, Pa., May 21, 2026 /PRNewswire/ -- Leading private markets asset management firm Hamilton Lane Incorporated (Nasdaq: HLNE) today reported its results for the fourth quarter and full fiscal year ended March 31, 2026.

On May 19, 2026, Hamilton Lane Inc (HLNE) shares fell 3.0%, closing at $84.11. The stock has been under pressure, trading within a 52-week range of $84.05 to $1

BRIDGEWATER, N.J.--(BUSINESS WIRE)-- #cosettepharma--Cosette Pharmaceuticals, Inc., a U.S.-based, branded specialty pharmaceutical company, announced today it has appointed David Bell as Chief Commercial Officer (Brands). David joins the company's executive leadership team as it continues to advance its ambitions in specialty pharmaceuticals and expand its commercial platform and portfolio. In this new role, David will oversee all branded commercial functions – including sales, marketing, market access, commerc.

Get a deeper insight into the potential performance of Hamilton Lane (HLNE) for the quarter ended March 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.